IL304588A - Anti-pd-l1 monoclonal antibodies and proteins fused to interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 - Google Patents
Anti-pd-l1 monoclonal antibodies and proteins fused to interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2Info
- Publication number
- IL304588A IL304588A IL304588A IL30458823A IL304588A IL 304588 A IL304588 A IL 304588A IL 304588 A IL304588 A IL 304588A IL 30458823 A IL30458823 A IL 30458823A IL 304588 A IL304588 A IL 304588A
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- receptor
- alpha
- monoclonal antibodies
- fusion proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140749P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013417 WO2022159771A1 (en) | 2021-01-22 | 2022-01-21 | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304588A true IL304588A (en) | 2023-09-01 |
Family
ID=80447580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304588A IL304588A (en) | 2021-01-22 | 2023-07-19 | Anti-pd-l1 monoclonal antibodies and proteins fused to interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340646A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4281186A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024504372A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230148169A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117083297A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022211410A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3205670A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304588A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022159771A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| AU2022306788A1 (en) * | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| WO2024263698A1 (en) * | 2023-06-22 | 2024-12-26 | Memorial Sloan-Kettering Cancer Center | Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof |
| CN120118196A (zh) * | 2023-12-08 | 2025-06-10 | 百奥泰生物制药股份有限公司 | 融合蛋白及其应用 |
| WO2025195291A1 (zh) * | 2024-03-16 | 2025-09-25 | 百奥泰生物制药股份有限公司 | 治疗肿瘤的方法和用途 |
| WO2026133288A2 (en) * | 2024-12-20 | 2026-06-25 | Sanofi | IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| IL131016A (en) | 1997-01-21 | 2004-12-15 | Gen Hospital Corp | Selection of proteins using RNA-protein blends |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| ES2774380T3 (es) * | 2014-08-29 | 2020-07-20 | Hoffmann La Roche | Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CA3116188A1 (en) * | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| WO2020081493A1 (en) * | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| WO2020165374A1 (en) * | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
-
2022
- 2022-01-21 JP JP2023544305A patent/JP2024504372A/ja active Pending
- 2022-01-21 KR KR1020237028520A patent/KR20230148169A/ko active Pending
- 2022-01-21 CN CN202280022519.2A patent/CN117083297A/zh active Pending
- 2022-01-21 US US18/262,122 patent/US20250340646A1/en active Pending
- 2022-01-21 AU AU2022211410A patent/AU2022211410A1/en active Pending
- 2022-01-21 CA CA3205670A patent/CA3205670A1/en active Pending
- 2022-01-21 WO PCT/US2022/013417 patent/WO2022159771A1/en not_active Ceased
- 2022-01-21 EP EP22703782.7A patent/EP4281186A1/en active Pending
-
2023
- 2023-07-19 IL IL304588A patent/IL304588A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250340646A1 (en) | 2025-11-06 |
| CA3205670A1 (en) | 2022-07-28 |
| KR20230148169A (ko) | 2023-10-24 |
| WO2022159771A1 (en) | 2022-07-28 |
| AU2022211410A1 (en) | 2023-08-10 |
| JP2024504372A (ja) | 2024-01-31 |
| CN117083297A (zh) | 2023-11-17 |
| EP4281186A1 (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278091A (en) | Heterodimeric 1-PD-targeted OH-FC proteins containing OH-IL-15/IL-15Rα FC proteins and 1-PD antigen binding regions and uses thereof | |
| IL278089A (en) | 3-TIM-targeted heterodimeric OH-FC proteins containing OH-IL-15/IL-15Rα FC proteins and 3-TIM antigen-binding domains | |
| SG11202010159RA (en) | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof | |
| IL271704A (en) | Targeted heterodimeric FC fusion proteins containing IL-15/IL-15Rα and antigen-binding domains | |
| EP4010378A4 (en) | ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF | |
| IL278088A (en) | Heterodimeric 3-LAG-targeted Ochi-FC proteins containing IL-15/IL-15Rα Ochi-FC proteins and 3-LAG antigen binding regions | |
| MY205418A (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| IL260218A (en) | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof | |
| TW200732350A (en) | Methods for generating monovalent IgG | |
| ECSP067073A (es) | Anticuerpos anti-il-13 y complejos | |
| ATE520716T1 (de) | Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften | |
| CY1118405T1 (el) | Διλειτουργικα πολυπεπτιδια | |
| DK0432249T3 (da) | Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf | |
| WO2004029092A3 (fr) | Anticorps pour adcc et induisant la production de cytokines. | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| IL304190A (en) | Anti-pd-l1 antibodies and their fusion proteins | |
| DK1974020T3 (da) | Fremgangsmåde til at opnå immortaliserede antistofudskillende celler | |
| EP4397684A4 (en) | MONOCLONAL ANTI-HUMAN TSLP ANTIBODY AND USE THEREOF | |
| IL311175A (en) | Anti-transferrin receptor antibodies and their uses | |
| AU2021462438B2 (en) | Anti-human interleukin-33 monoclonal antibody and use thereof | |
| DK1519748T3 (da) | Mikropartikler med CD28-specifikke monoklonale antistoffer | |
| IL306074A (en) | UPAR antibodies and fusion proteins with them | |
| SMT202600020T1 (it) | Anticorpi monoclonali anti-gprc5d e usi di essi | |
| IL299238A (en) | Anti-pd-1 antibodies and fusion proteins | |
| IL315438A (en) | New anti-CD3 antibodies and their uses |